^Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E.; Sharmin, Dishary; Pandey, Kamal P.; Mian, Md Yeunus; Cook, James M.; Cerne, Rok (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology Biochemistry and Behavior. 213: 173321.
doi:
10.1016/j.pbb.2021.173321.
PMID35041859.
S2CID245963990.
^Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428.
doi:
10.1097/JCP.0000000000001591.
PMID36099401.
S2CID252219658.
^Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E.; Sharmin, Dishary; Pandey, Kamal P.; Mian, Md Yeunus; Cook, James M.; Cerne, Rok (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology Biochemistry and Behavior. 213: 173321.
doi:
10.1016/j.pbb.2021.173321.
PMID35041859.
S2CID245963990.
^Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428.
doi:
10.1097/JCP.0000000000001591.
PMID36099401.
S2CID252219658.